UnitedHealth Group Inc. operates in 4 segments: UnitedHealthcare; Optum Health; Optum Insight; and Optum Rx.
- Segment Profit Margin
- Segment Return on Assets (Segment ROA)
- Segment Asset Turnover
- Segment Capital Expenditures to Depreciation
- Revenues, including investment and other income
- Earnings before income taxes
- Total assets
- Purchases of property, equipment and capitalized software
- Depreciation and amortization
Paying user area
Try for free
UnitedHealth Group Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to UnitedHealth Group Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Segment Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- UnitedHealthcare Profit Margin Trend
- The profit margin for UnitedHealthcare exhibited a declining trend from 6.15% in 2020 to 5.37% in 2021, followed by a modest recovery to 5.83% in 2023. However, a significant drop to 2.44% was observed in 2024, indicating a sharp decrease in profitability in the most recent year.
- Optum Health Profit Margin Trend
- Optum Health showed a gradual decline in profit margin from 8.63% in 2020 to 6.88% in 2023, with a slight rebound to 7.37% in 2024. The variation suggests some volatility but generally maintaining a profit margin above 6% throughout the period.
- Optum Insight Profit Margin Trend
- Optum Insight displayed the highest profit margins among the segments but with a downward trajectory. Starting at 25.23% in 2020, the margin peaked at 27.85% in 2021 before decreasing consistently to 16.51% by 2024. This represents a substantial reduction over the five-year span, signaling potential challenges or increased costs impacting profitability.
- Optum Rx Profit Margin Trend
- Optum Rx maintained relatively stable profit margins throughout the period, fluctuating slightly around 4.4% to 4.5%. The margin showed minimal variation, ending at 4.38% in 2024, reflecting steady but modest profitability.
- Overall Observations
- The analysis reveals a general pattern of declining profitability across most segments, notably in UnitedHealthcare and Optum Insight. Optum Health experienced a moderate decline with some recovery, while Optum Rx remained relatively stable. The sharp decline in UnitedHealthcare's margin in the final year is especially notable and may warrant further investigation into the underlying causes.
Segment Profit Margin: UnitedHealthcare
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Revenues, including investment and other income | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Earnings before income taxes ÷ Revenues, including investment and other income
= 100 × ÷ =
- Earnings before income taxes
- The earnings before income taxes exhibited a fluctuating trend over the five-year period. Starting at 12,359 million USD in 2020, the figure decreased slightly to 11,975 million USD in 2021. Thereafter, it increased substantially to 14,379 million USD in 2022 and continued rising to 16,415 million USD in 2023. However, in 2024, there was a significant decline to 7,274 million USD, representing a notable decrease compared to the previous two years.
- Revenues, including investment and other income
- Revenues showed a consistent upward trend throughout the entire period. Beginning at 200,875 million USD in 2020, revenues rose steadily each year, reaching 222,899 million USD in 2021, 249,741 million USD in 2022, 281,360 million USD in 2023, and 298,208 million USD in 2024. This indicates a strong and continuous growth in overall revenue generation.
- Segment profit margin
- The segment profit margin demonstrated variability over the years. It decreased from 6.15% in 2020 to 5.37% in 2021, followed by a moderate recovery to 5.76% in 2022 and a slight increase to 5.83% in 2023. However, in 2024, the margin sharply declined to 2.44%, which represents a significant contraction compared to previous years. This decline suggests reduced profitability relative to revenues in the most recent period.
Segment Profit Margin: Optum Health
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Revenues, including investment and other income | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Earnings before income taxes ÷ Revenues, including investment and other income
= 100 × ÷ =
- Earnings before income taxes
- There is a clear upward trend in earnings before income taxes over the five-year period. The amount increased steadily from $3,434 million in 2020 to $7,770 million in 2024. The growth accelerated notably between 2021 and 2022, with a somewhat slower but consistent rise through 2023 and 2024.
- Revenues, including investment and other income
- Revenues displayed substantial growth throughout the period, rising from $39,808 million in 2020 to $105,358 million in 2024. The increase was especially pronounced between 2021 and 2023, with a slightly moderated but still significant advancement into 2024.
- Segment profit margin
- The segment profit margin showed some fluctuations over the timeframe. Initially, it decreased from 8.63% in 2020 to 8.25% in 2021, followed by a slight recovery to 8.48% in 2022. However, it then declined more sharply in 2023 to 6.88% before showing a moderate improvement to 7.37% in 2024. This pattern indicates some pressure on profitability relative to revenues despite growing earnings.
Segment Profit Margin: Optum Insight
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Revenues, including investment and other income | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Earnings before income taxes ÷ Revenues, including investment and other income
= 100 × ÷ =
- Earnings before income taxes
- The earnings before income taxes demonstrated an overall upward trend from 2020 through 2023, starting at 2,725 million US dollars in 2020 and peaking at 4,268 million US dollars in 2023. However, in 2024, there was a notable decrease to 3,097 million US dollars, indicating a reversal from the prior growth.
- Revenues, including investment and other income
- The revenues for the segment showed consistent growth from 2020 to 2023. Revenues increased from 10,802 million US dollars in 2020 to a high of 18,932 million US dollars in 2023. In 2024, revenues slightly declined to 18,757 million US dollars, which is marginally lower than the previous year but still considerably higher compared to the earlier periods.
- Segment profit margin
- The segment profit margin experienced a steady decline over the reported years. Starting at 25.23% in 2020, the margin rose to a peak of 27.85% in 2021. After this peak, it consistently decreased, reaching 16.51% in 2024. This downward trend indicates increased pressure on profitability despite rising revenues through most of the period.
Segment Profit Margin: Optum Rx
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Revenues, including investment and other income | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Earnings before income taxes ÷ Revenues, including investment and other income
= 100 × ÷ =
- Earnings Before Income Taxes
- The earnings before income taxes show a consistent upward trend over the observed periods. Starting at $3,887 million in 2020, the figure increased annually, reaching $5,836 million by 2024. This represents a significant growth, indicating improved profitability at the segment level year over year.
- Revenues, Including Investment and Other Income
- Revenues display a steady and substantial increase throughout the five-year span. Beginning at $87,498 million in 2020, revenues rose continuously to $133,231 million by the end of 2024. The growth suggests strong expansion in the segment’s top-line performance, reflecting higher sales volume, pricing power, or a combination thereof.
- Segment Profit Margin
- The segment profit margin remains relatively stable but shows a slight declining trend. Starting at 4.44% in 2020, it fluctuates marginally but gradually decreases to 4.38% by 2024. This minor decline in profit margin, despite rising revenues and earnings, may imply increased costs or investments within the segment, affecting profitability ratios.
- Overall Trends and Insights
- The segment demonstrates robust growth in both revenues and earnings before income taxes, indicating strong operational performance and expansion. However, the small erosion in profit margin suggests that cost management or cost structure changes may be areas requiring attention to ensure sustained profitability improvements. The data reflects a generally positive financial trajectory, with increased scale balanced against maintaining profit efficiency.
Segment Return on Assets (Segment ROA)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- UnitedHealthcare Segment ROA
- The Return on Assets (ROA) for the UnitedHealthcare segment exhibited moderate fluctuations over the five-year period. Starting at 12.58% in 2020, there was a slight decline to 11.63% in 2021. Subsequently, the ROA increased notably, reaching a peak of 14.8% in 2023. However, in 2024, the ROA sharply declined to 6.11%, marking a significant decrease compared to prior years. This indicates a considerable reduction in asset efficiency or profitability in the latest year.
- Optum Health Segment ROA
- The Optum Health segment demonstrated a generally positive trend in ROA from 2020 to 2024. The ROA grew from 6.59% in 2020 to 7.38% in 2021, followed by a further increase to 8.75% in 2022. Although there was a slight dip to 7.34% in 2023, the figure rose again to 8.05% in 2024. This pattern reflects an overall improving or stable performance in asset utilization within this segment, despite the minor temporary decline.
- Optum Insight Segment ROA
- The ROA for Optum Insight displayed more volatility compared to other segments. After increasing from 17.67% in 2020 to a high of 20.14% in 2021, there was a sharp decline to 11.54% in 2022. This was followed by a slight recovery to 12.49% in 2023, but the ROA decreased again to 8.99% in 2024. The overall trend indicates a declining efficiency or profitability in asset usage for this segment after peaking in 2021.
- Optum Rx Segment ROA
- The Optum Rx segment showed relative stability in its ROA during the period analyzed. The values ranged narrowly between 9.34% and 10.29%, beginning with 9.9% in 2020 and slightly increasing to 10.29% in 2021. Following a minor decline to 9.34% in 2022, the ROA rose again to 9.98% in 2023 and then slightly decreased to 9.88% in 2024. This steady pattern suggests consistent asset profitability without significant fluctuations.
Segment ROA: UnitedHealthcare
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Earnings before income taxes ÷ Total assets
= 100 × ÷ =
The segment demonstrated fluctuating profitability and asset growth over the observed periods. Earnings before income taxes showed a general upward trajectory from 12,359 million US dollars in 2020 to a peak of 16,415 million US dollars in 2023, followed by a significant decline to 7,274 million US dollars in 2024.
Total assets consistently increased each year, rising from 98,229 million US dollars in 2020 to 119,009 million US dollars in 2024, indicating ongoing asset accumulation and expansion within the segment.
The segment return on assets (ROA) mirrored the earnings trend, starting at 12.58% in 2020, experiencing a slight dip in 2021 to 11.63%, then increasing steadily to 14.8% in 2023 before dropping sharply to 6.11% in 2024. This suggests that asset utilization efficiency improved until 2023 but deteriorated notably in 2024.
- Earnings before income taxes
- Displayed growth from 2020 through 2023, peaking in 2023 before declining markedly in 2024, which may signal underlying challenges impacting profitability in the latest period.
- Total assets
- Followed a consistent upward trend throughout the period, reflecting ongoing investment and asset base expansion.
- Segment ROA
- Indicated enhanced efficiency and profitability relative to assets up to 2023, with a significant fall in 2024 that aligns with the drop in earnings, implying reduced returns on the expanded asset base.
Overall, the data points to sustained growth and improving efficiency until 2023, succeeded by a marked contraction in profitability and returns in 2024 despite continued asset growth. This pattern warrants further analysis to identify factors contributing to the earnings and ROA decline in the most recent year.
Segment ROA: Optum Health
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Earnings before income taxes ÷ Total assets
= 100 × ÷ =
The analysis of the Optum Health segment over the five-year period reveals several key financial trends and performance indicators.
- Earnings Before Income Taxes
- The earnings before income taxes have shown a consistent upward trajectory from 2020 through 2024. Starting at $3,434 million in 2020, earnings increased steadily each year to reach $7,770 million by 2024. This represents more than a doubling of earnings over the five-year span, suggesting strong profitability growth in the segment.
- Total Assets
- Total assets have also grown significantly, increasing from $52,073 million in 2020 to $96,472 million in 2024. This asset growth indicates expansion and possibly increased investment or acquisitions within the segment, enhancing its operational capacity and potential revenue-generating ability.
- Segment Return on Assets (ROA)
- The segment ROA fluctuated during the period but generally remained in a range indicative of solid asset utilization. It started at 6.59% in 2020, peaked at 8.75% in 2022, then dipped to 7.34% in 2023 before rising again to 8.05% in 2024. These fluctuations suggest some variability in how effectively the segment’s assets are being used to generate earnings, with 2022 marking a notable high point in efficiency.
Overall, the Optum Health segment exhibits strong growth in earnings and asset base over the examined periods, with a generally high and somewhat volatile return on assets. These trends indicate an expanding and increasingly profitable segment with fluctuations in asset efficiency that may merit further examination to understand underlying causes.
Segment ROA: Optum Insight
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Earnings before income taxes ÷ Total assets
= 100 × ÷ =
- Earnings before income taxes
- The earnings before income taxes demonstrated an overall increasing trend from 2020 to 2023, starting at 2,725 million US dollars and peaking at 4,268 million in 2023. However, in 2024, there was a notable decrease to 3,097 million, marking a decline from the previous year despite still being higher than the initial years.
- Total assets
- Total assets exhibited substantial growth throughout the five-year period. From 15,425 million US dollars in 2020, assets increased significantly to 34,452 million by 2024. The most pronounced acceleration occurred between 2021 and 2022, when total assets nearly doubled, suggesting major investments or acquisitions during this period.
- Segment ROA
- The segment return on assets (ROA) showed variability with an initial increase from 17.67% in 2020 to a peak of 20.14% in 2021. Subsequently, there was a sharp decline in 2022 to 11.54%, followed by modest improvement in 2023 to 12.49%. In 2024, ROA decreased again to 8.99%, the lowest point in the five-year span, indicating diminishing efficiency in generating profits relative to assets.
Segment ROA: Optum Rx
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Earnings before income taxes | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Earnings before income taxes ÷ Total assets
= 100 × ÷ =
- Earnings before income taxes
- The earnings before income taxes exhibit a consistent upward trend over the five-year period, increasing from $3,887 million in 2020 to $5,836 million in 2024. This represents a substantial growth, indicating improved profitability before tax obligations. The annual increments demonstrate a steady increase, with the most notable rise occurring between 2022 and 2023.
- Total assets
- Total assets also show a steady increase from $39,280 million in 2020 to $59,086 million in 2024. The growth reflects an expansion in the segment’s asset base, with a noticeable acceleration in asset accumulation between 2021 and 2022, and continuing at a healthy pace through 2024. This expansion suggests ongoing investment or asset retention strategies supporting future operations.
- Segment ROA (Return on Assets)
- The segment ROA remains relatively stable across the period, fluctuating slightly but maintaining a range between approximately 9.3% and 10.3%. After a peak of 10.29% in 2021, there is a slight decline in 2022 to 9.34%, followed by recovery to near 10% levels in 2023 and 2024. This indicates that while the asset base and earnings have grown, the efficiency in generating income from assets has remained consistent without significant improvements or deteriorations.
- Overall analysis
- The data portrays a segment characterized by robust earnings growth and asset expansion over five years, with a steady and stable return on assets. The combination of increased earnings and asset growth, alongside a consistent ROA, suggests effective management of assets to sustain profitability. The slight fluctuations in ROA imply normal variations in operational efficiency, but no major changes to the segment’s financial health or asset utilization.
Segment Asset Turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- UnitedHealthcare
- The asset turnover ratio for UnitedHealthcare has exhibited a consistent upward trend from 2.04 in 2020 to a peak of 2.54 in 2023, followed by a slight decline to 2.51 in 2024. This suggests improving efficiency in utilizing assets to generate revenue over the observed period, with a minor deceleration in the most recent year.
- Optum Health
- Optum Health shows a steady increase in asset turnover ratio, rising from 0.76 in 2020 to 1.09 in 2024. The growth rate appears to moderate slightly in later years, indicating ongoing but slower improvement in asset management effectiveness.
- Optum Insight
- This segment demonstrates a more varied pattern. The ratio increased slightly from 0.70 in 2020 to 0.72 in 2021 but then substantially declined to 0.47 in 2022. It showed some recovery to 0.55 in 2023 but slightly decreased again to 0.54 in 2024. This variability indicates instability or changes in operational efficiency or asset utilization in recent years.
- Optum Rx
- The asset turnover ratio for Optum Rx remained relatively stable, fluctuating marginally between 2.10 and 2.27 over the five-year period. After a slight dip to 2.10 in 2022, it rebounded to about 2.25 by 2024, reflecting consistent asset utilization performance with minor short-term variations.
Segment Asset Turnover: UnitedHealthcare
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues, including investment and other income | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Revenues, including investment and other income ÷ Total assets
= ÷ =
- Revenues, including investment and other income
- Revenues exhibited a consistent upward trend over the five-year period. Starting at 200,875 million USD in 2020, revenues increased year-over-year, reaching 298,208 million USD by 2024. This represents a cumulative increase of approximately 48.5% from 2020 to 2024, indicating robust growth in revenue generation within this segment.
- Total assets
- Total assets also showed steady growth throughout the period analyzed. Beginning at 98,229 million USD in 2020, assets rose gradually each year, reaching 119,009 million USD by 2024. This reflects a moderate but consistent asset base expansion, with a total increase of about 21.1% over five years.
- Segment asset turnover
- The segment asset turnover ratio demonstrated an overall positive trend from 2020 through 2023, improving from 2.04 to a peak of 2.54. This suggests increasing efficiency in generating revenues from the asset base. However, the ratio slightly declined to 2.51 in 2024, indicating a minor decrease in asset utilization efficiency in the most recent year, though remaining substantially higher than the 2020 baseline.
- Overall insights
- The data reflect a period of solid growth and improving operational efficiency. Revenue growth outpaced asset growth, contributing to the rising asset turnover ratio over the four years until 2023. The slight dip in asset turnover in 2024 warrants attention but does not significantly detract from the overall positive trend. The increase in total assets aligns with the need to support growing operations and revenue streams.
Segment Asset Turnover: Optum Health
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues, including investment and other income | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Revenues, including investment and other income ÷ Total assets
= ÷ =
- Revenues, including investment and other income
- Revenues demonstrated a consistent and strong upward trend over the five-year period. Starting from $39,808 million in 2020, revenues increased substantially to $54,065 million in 2021, then to $71,174 million in 2022. This positive momentum continued with revenues reaching $95,319 million in 2023, and further rising to $105,358 million in 2024. Overall, revenues grew by approximately 164% from 2020 to 2024, indicating robust growth in the segment's income generation capabilities.
- Total assets
- Total assets also exhibited steady growth, increasing from $52,073 million at the end of 2020 to $60,474 million in 2021, and then to $68,950 million in 2022. The asset base experienced accelerated expansion thereafter, reaching $89,432 million in 2023 and $96,472 million in 2024. Over the five years, total assets grew by about 85%, reflecting ongoing investments or asset accumulation in the segment.
- Segment asset turnover
- This ratio, which measures the efficiency of asset use in generating revenue, improved progressively each year. Beginning at 0.76 in 2020, it rose to 0.89 in 2021 and crossed the 1.0 threshold in 2022 with a value of 1.03. The upward trend continued with values of 1.07 in 2023 and 1.09 in 2024. This indicates increasing effectiveness in utilizing assets to produce revenue over the period, reinforcing operational efficiency gains.
Segment Asset Turnover: Optum Insight
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues, including investment and other income | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Revenues, including investment and other income ÷ Total assets
= ÷ =
- Revenues, including investment and other income
- The revenue figures demonstrate a consistent upward trend from 2020 to 2023, increasing from $10,802 million in 2020 to a peak of $18,932 million in 2023. However, in 2024, there is a slight decline to $18,757 million, indicating a marginal decrease after several years of growth.
- Total assets
- Total assets exhibit significant growth over the period, nearly doubling from $15,425 million in 2020 to $31,090 million in 2022. The upward trend continues at a slower pace in subsequent years, reaching $34,452 million in 2024.
- Segment asset turnover
- The segment asset turnover ratio shows a declining trend from 0.7 in 2020 to 0.47 in 2022, suggesting that asset efficiency decreased during this period. Although there is a partial recovery in 2023 and 2024 with ratios of 0.55 and 0.54 respectively, the turnover remains below the initial 2020 level, indicating that revenue generation per unit of asset has not fully rebounded.
Segment Asset Turnover: Optum Rx
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues, including investment and other income | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Revenues, including investment and other income ÷ Total assets
= ÷ =
- Revenues, including investment and other income
- The revenues exhibited a consistent upward trend over the reviewed period. Starting at approximately $87.5 billion in 2020, revenues increased annually to reach about $133.2 billion by the end of 2024. This represents a compound growth pattern, with the most substantial increases observed between 2022 and 2024, indicating robust expansion in the segment's income generation capabilities.
- Total assets
- Total assets also showed a progressive increase throughout the period, growing from around $39.3 billion in 2020 to nearly $59.1 billion in 2024. The asset base expanded steadily each year, reflecting ongoing investment or accumulation of resources within the segment. The asset growth appears consistent with the revenue increase, suggesting scaling operations or strategic asset acquisitions.
- Segment asset turnover
- The segment asset turnover ratio, which measures the efficiency of asset utilization in generating revenues, remained relatively stable over the years. Beginning at 2.23 in 2020, the ratio saw a slight increase to 2.27 in 2021, then dipped to 2.10 in 2022. It rebounded to 2.26 in 2023 and settled at 2.25 in 2024. This stability implies that despite changes in asset levels and revenues, the segment maintained consistent operational efficiency in producing income from its assets.
- Overall analysis
- The data reflects a growth-oriented segment, with revenues and assets both increasing substantially over the five-year span. The consistent asset turnover ratio suggests that the growth in revenues is generally aligned with asset investments, without significant deterioration or improvement in efficiency. This pattern indicates steady performance, with the segment effectively leveraging its assets to support expanding revenue streams.
Segment Capital Expenditures to Depreciation
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The analysis of the annual reportable segment capital expenditures to depreciation ratios over the five-year period reveals distinct trends across the four primary segments.
- UnitedHealthcare
- The ratio for UnitedHealthcare shows a consistent upward trajectory from 0.75 in 2020 to 0.88 in both 2023 and 2024. This steady increase suggests a gradual rise in capital expenditures relative to depreciation, indicating ongoing investment in assets or infrastructure enhancements within this segment.
- Optum Health
- This segment demonstrates some variability with an initial decline from 1.02 in 2020 to 0.97 in 2021, followed by an increase to 1.13 in 2023 and a notable decrease to 0.9 in 2024. The peak in 2023 may reflect a surge in capital spending or strategic expansion, whereas the subsequent drop could indicate a tapering of investments or higher depreciation expenses.
- Optum Insight
- The ratio for Optum Insight increases moderately from 0.69 in 2020 to 0.83 in 2021 and 2022, then dips slightly to 0.79 in 2023 before rising sharply to 1.00 in 2024. This pattern suggests relatively stable investment levels initially, with a significant rise in capital expenditures relative to depreciation in the latest period, potentially pointing to new initiatives or asset acquisitions.
- Optum Rx
- The Optum Rx segment exhibits a clear upward trend starting at 0.31 in 2020 and advancing steadily to 0.53 in 2024. Though the ratios remain below those of other segments, the consistent increase signals ongoing growth in capital investments when compared to depreciation levels.
In summary, all segments display an overall growth trend in capital expenditures relative to depreciation over the observed period, with differing rates and patterns. UnitedHealthcare and Optum Rx show steady increases, Optum Health presents more fluctuation around a high peak, and Optum Insight culminates with a significant rise in the final year. These trends likely reflect strategic investment decisions aligned with each segment’s operational focus and growth opportunities.
Segment Capital Expenditures to Depreciation: UnitedHealthcare
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Purchases of property, equipment and capitalized software | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Purchases of property, equipment and capitalized software ÷ Depreciation and amortization
= ÷ =
The data presents key capital investment and amortization metrics for the UnitedHealthcare segment over a five-year period from 2020 to 2024. The analysis focuses on capital expenditures, depreciation and amortization expenses, and the ratio of capital expenditures to depreciation.
- Capital Expenditures (Purchases of Property, Equipment, and Capitalized Software)
- There is an overall increasing trend in capital expenditures from 2020 to 2023, rising from $687 million in 2020 to a peak of $866 million in 2023. However, in 2024, capital spending decreased to $781 million, representing a moderation after the prior years' growth.
- Depreciation and Amortization
- Depreciation and amortization expenses grew steadily from $920 million in 2020 to $1,004 million in 2021. Subsequently, this expense exhibited a slight declining pattern, reducing to $973 million in 2022 and remaining relatively stable at $989 million in 2023, before decreasing further to $889 million in 2024.
- Segment Capital Expenditures to Depreciation Ratio
- The ratio of capital expenditures to depreciation increased steadily over the analyzed period, starting at 0.75 in 2020 and gradually rising each year to reach 0.88 in both 2023 and 2024. This suggests that capital spending has been increasing relative to the depreciation expense, approaching parity as of the latest year.
Overall, the data indicates increased capital investment activity in the segment through 2023, followed by a slight decline in 2024. At the same time, the depreciation and amortization expenses have declined after peaking in 2021, creating an environment where capital expenditures have grown to nearly match the level of depreciation. This growing ratio may imply ongoing efforts to maintain or renew the segment's asset base at a level close to the asset consumption represented by depreciation.
Segment Capital Expenditures to Depreciation: Optum Health
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Purchases of property, equipment and capitalized software | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Purchases of property, equipment and capitalized software ÷ Depreciation and amortization
= ÷ =
The analysis of the annual data reveals distinct trends in the capital expenditure and depreciation activities over the five-year period.
- Purchases of property, equipment, and capitalized software
- There is a general upward trend in acquisitions, rising from 715 million US dollars in 2020 to a peak of 1,199 million in 2023, followed by a decline to 1,008 million in 2024. This pattern indicates increasing investment intensity until 2023, with a subsequent moderation.
- Depreciation and amortization
- This expense exhibits a consistent growth pattern throughout the five years, increasing steadily from 703 million US dollars in 2020 to 1,123 million in 2024. This continuous rise suggests a growing asset base being depreciated over time.
- Segment capital expenditures to depreciation ratio
- The ratio fluctuates around the 1.0 mark, starting at 1.02 in 2020, dipping slightly below 1.0 in 2021, and then rising to a high of 1.13 in 2023 before dropping to 0.9 in 2024. A ratio above 1 generally indicates capital expenditures exceed depreciation, implying asset base growth, whereas a ratio below 1 suggests capital expenditures are not sufficient to cover depreciation, potentially indicating a slowdown in asset expansion or reinvestment.
Overall, the data reflects a phase of increasing investment in assets up to 2023 accompanied by steadily increasing depreciation, followed by a reduction in new capital expenditures relative to depreciation in 2024, signaling a potential adjustment in investment strategy or asset base growth rate.
Segment Capital Expenditures to Depreciation: Optum Insight
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Purchases of property, equipment and capitalized software | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Purchases of property, equipment and capitalized software ÷ Depreciation and amortization
= ÷ =
Over the examined period, there is a clear upward trend in the purchases of property, equipment, and capitalized software. Starting at $461 million in 2020, these expenditures steadily increased each year, reaching $1,291 million by 2024. This signifies a substantial investment growth in the segment’s fixed assets and capitalized software.
Depreciation and amortization expenses also show a consistent increasing pattern, beginning at $670 million in 2020 and rising to $1,294 million in 2024. This trend reflects the aging and usage of the capital assets, as well as the impact of prior investments being amortized or depreciated over time.
- Purchases of Property, Equipment, and Capitalized Software
- There is a more than doubling of capital investments over the five-year span, indicating an aggressive expansion or upgrading strategy in assets and software within the segment.
- Depreciation and Amortization
- These expenses have nearly doubled in the same timeframe, pointing to increased asset base and potentially accelerated amortization schedules related to recent capital expenditures.
- Segment Capital Expenditures to Depreciation Ratio
- The ratio fluctuates moderately around values close to 0.8 until 2023, initially suggesting that capital expenditures were less than annual depreciation/amortization, possibly signaling asset base contraction or steady state. However, in 2024, the ratio reaches 1.0, implying capital expenditures equaled depreciation for the first time in the period, potentially indicating stabilization or growth in asset investment relative to asset consumption.
Overall, the data reveal a robust trend of increasing capital spending, with depreciation and amortization correspondingly increasing, reflecting asset growth and utilization within the segment. The movement of the capital expenditures to depreciation ratio towards unity in the final year suggests the segment may be shifting towards a maintenance or expansion investment cycle after several years of relatively lower capital investment intensity compared to asset write-offs.
Segment Capital Expenditures to Depreciation: Optum Rx
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Purchases of property, equipment and capitalized software | |||||
Depreciation and amortization | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Purchases of property, equipment and capitalized software ÷ Depreciation and amortization
= ÷ =
- Purchases of property, equipment and capitalized software
- There has been a consistent increase in capital expenditures over the five-year period. Starting at 188 million US dollars in 2020, the amount nearly doubled by 2024, reaching 419 million US dollars. This suggests a sustained investment in property, equipment, and software development within the segment.
- Depreciation and amortization
- Depreciation and amortization expenses have also shown a steady upward trend. From 598 million US dollars in 2020, these expenses increased each year, reaching 793 million US dollars in 2024. This indicates growth in the depreciable asset base, consistent with the rising capital expenditures.
- Segment capital expenditures to depreciation ratio
- The ratio of capital expenditures to depreciation remained relatively stable but showed a slight increasing trend, beginning at 0.31 in 2020 and rising to 0.53 by 2024. This reflects that capital investments are growing at a rate slightly higher than depreciation expenses, which may signal ongoing expansion or asset refreshment efforts within the segment.
Revenues, including investment and other income
UnitedHealth Group Inc., revenues, including investment and other income by reportable segment
US$ in millions
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx | |||||
Optum Eliminations | |||||
Optum | |||||
Corporate and Eliminations | |||||
Consolidated |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The analysis of the annual segment revenues and investment and other income data shows consistent growth across most business segments over the five-year period.
- UnitedHealthcare
- This segment exhibits a steady upward trend, with revenues increasing each year from US$200,875 million in 2020 to US$298,208 million in 2024. The growth indicates strong performance and expanding operations within this core healthcare service segment.
- Optum Health
- Revenues show a significant increase from US$39,808 million in 2020 to US$105,358 million in 2024, indicating more than doubling over five years. This segment demonstrates robust growth, likely driven by increased demand for health services and possibly expanded offerings.
- Optum Insight
- The segment experiences consistent growth from US$10,802 million in 2020 to a peak of US$18,932 million in 2023, though a slight decline to US$18,757 million is noted in 2024. Overall, the trend remains upward, reflecting increasing analytics and technology services, despite the minor dip in the latest period.
- Optum Rx
- Revenues progressively increased from US$87,498 million in 2020 to US$133,231 million in 2024. The steady growth emphasizes expanding pharmaceutical services and prescription management operations within the company.
- Optum Eliminations
- Negative values increasing in magnitude from -US$1,800 million in 2020 to -US$4,389 million in 2024 indicate larger internal eliminations within the Optum segments, which is consistent with the rise in consolidated Optum revenues. This suggests increased intersegment transactions related to growing operations.
- Optum (consolidated)
- Aggregate Optum revenues consistently rise from US$136,308 million in 2020 to US$252,957 million in 2024, showing strong, continuous growth. The combined growth across its subsegments highlights Optum’s expanding contribution to the overall business.
- Corporate and Eliminations
- The negative figures, representing corporate expenses and intersegment eliminations, grow from -US$80,042 million in 2020 to -US$150,887 million in 2024. This trend suggests increasing management costs and intercompany adjustments reflecting the growth of consolidated operations.
- Consolidated Revenues
- The total consolidated revenues display a robust increase over the five years, from US$257,141 million in 2020 to US$400,278 million in 2024. This indicates overall business expansion and revenue growth, driven primarily by strong increases in UnitedHealthcare and Optum segments.
In summary, all major business segments demonstrate consistent revenue growth over the period, with Optum segments showing especially rapid increases. Despite increased intersegment eliminations and corporate costs, the company's consolidated revenues reveal strong overall growth momentum year over year.
Earnings before income taxes
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx | |||||
Optum | |||||
Corporate and Eliminations | |||||
Consolidated |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The earnings before income taxes data over the five-year period show varying trends across different reportable segments, reflecting fluctuations in financial performance and possible strategic shifts.
- UnitedHealthcare
- This segment displays a fluctuating pattern with initial earnings of 12,359 million US dollars in 2020, dipping slightly in 2021 to 11,975 million. A significant increase occurs in 2022 and 2023, reaching 14,379 million and 16,415 million respectively, indicating robust growth. However, in 2024 there is a notable decline to 7,274 million, which might suggest either operational challenges or market conditions impacting performance.
- Optum Health
- There is a consistent upward trajectory in earnings within Optum Health. Starting from 3,434 million in 2020, earnings rise steadily each year, reaching 7,770 million in 2024. This represents more than doubling over the period, suggesting strong expansion and possibly increased market share or efficiency improvements.
- Optum Insight
- This segment experiences growth from 2,725 million in 2020 to a peak of 4,268 million in 2023, emphasizing a positive upward trend. However, a decline to 3,097 million in 2024 interrupts this pattern, indicating a potential downturn or restructuring effect late in the period.
- Optum Rx
- Optum Rx shows steady earnings increases throughout the period analyzed, starting at 3,887 million in 2020 and progressing to 5,836 million by 2024. This continued growth underscores sustained operational success within this business area.
- Optum (combined)
- The combined Optum segments demonstrate an overall strong and consistent rise in earnings before income taxes, increasing from 10,046 million in 2020 to 16,703 million in 2024. Despite a minor dip in the individual Optum Insight line in 2024, the consolidated Optum figure continues to grow, reflecting the strength of the integrated services business.
- Corporate and Eliminations
- This category reflects negative earnings throughout the entire period, with losses increasing from -1,663 million in 2020 to -3,906 million in 2024. The escalation of negative figures suggests rising corporate costs, eliminations, or adjustments impacting consolidated totals adversely.
- Consolidated Earnings
- Consolidated earnings before income taxes show growth from 20,742 million in 2020 to a high of 29,112 million in 2023, indicating overall financial strength. However, a decrease to 20,071 million in 2024 signals a significant reduction that corresponds with declines noted in UnitedHealthcare and the increased corporate losses, which together tempered the positive growth seen in the Optum segments.
Overall, the data present a mixed picture: the Optum businesses exhibit strong, mostly consistent growth, which is partly offset by the volatility in UnitedHealthcare and steadily increasing corporate losses. This suggests that while certain core operating segments are performing well, challenges remain in others, impacting consolidated profitability.
Total assets
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx | |||||
Optum | |||||
Corporate and Eliminations | |||||
Consolidated |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The total assets data exhibits a consistent upward trend across the majority of segments over the five-year period from 2020 to 2024. Each segment demonstrates varying rates of growth, reflecting shifts in asset allocation and potential strategic focus within the organization.
- UnitedHealthcare
- Assets increased steadily from $98.2 billion in 2020 to $119.0 billion in 2024. This reflects a moderate but continuous expansion, with the compound annual growth rate suggesting stable development in the core healthcare segment.
- Optum Health
- This segment shows significant growth from $52.1 billion in 2020 to $96.5 billion in 2024. The asset base almost doubled over the five years, with a pronounced acceleration in the latter years, indicating increased investment or asset accumulation in health services.
- Optum Insight
- Optum Insight's assets nearly doubled between 2020 ($15.4 billion) and 2022 ($31.1 billion), followed by a slower growth trajectory, reaching $34.5 billion by 2024. The sharp increase in the early period suggests substantial acquisition or development of intellectual property, technology, or data analytics assets.
- Optum Rx
- The segment exhibited steady growth from $39.3 billion in 2020 to $59.1 billion in 2024. The increase appears linear and consistent, indicating stable expansion likely aligned with pharmacy care services growth trends and strategic investments.
- Optum Total
- Aggregating the three Optum components, total assets grew from $106.8 billion in 2020 to $190.0 billion in 2024. This reflects a robust expansion rate outpacing the UnitedHealthcare segment, underscoring Optum's increasing prominence within the overall business structure.
- Corporate and Eliminations
- Negative values, representing corporate-level adjustments and intersegment eliminations, increased in absolute value from -$7.7 billion in 2020 to a peak negative adjustment of -$12.1 billion in 2023 before decreasing slightly to -$10.7 billion in 2024. These fluctuations suggest variability in internal transactions or asset reclassifications impacting consolidated totals.
- Consolidated
- The consolidated total assets demonstrate a strong upward progression from $197.3 billion in 2020 to $298.3 billion in 2024. This reflects an overall asset growth of approximately 51% over the five years, driven primarily by significant increases within the Optum segments and steady growth in UnitedHealthcare.
Purchases of property, equipment and capitalized software
UnitedHealth Group Inc., purchases of property, equipment and capitalized software by reportable segment
US$ in millions
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx | |||||
Optum | |||||
Consolidated |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The data on annual reportable segment purchases of property, equipment, and capitalized software reveals several notable trends across different segments over the five-year period.
- UnitedHealthcare Segment
- Purchases exhibited a moderate increase from 687 million US dollars in 2020 to a peak of 866 million in 2023, followed by a decline to 781 million in 2024. This indicates some volatility but overall a slight upward trend with a recent reduction.
- Optum Health Segment
- This segment demonstrated a consistent increase from 715 million in 2020 to 1,199 million in 2023, though it decreased to 1,008 million in 2024. Despite the recent drop, the values remain significantly higher than the initial year, reflecting substantial capital investment growth over the period.
- Optum Insight Segment
- There is a strong positive trend, with values rising steadily each year from 461 million in 2020 to 1,291 million in 2024. This segment shows the most pronounced growth, more than doubling the capital expenditures across the time frame.
- Optum Rx Segment
- Purchases increased from 188 million in 2020 to 419 million in 2024, indicating a steady growth trajectory. The increase is consistent, without any recorded decrease year-over-year.
- Optum Consolidated
- The consolidated Optum segment, encompassing its subsegments, shows a continuous upward movement in purchases, ascending from 1,364 million in 2020 to 2,718 million in 2024. This reflects a notable expansion in capital investment within the combined Optum business units.
- Overall Consolidated Purchases
- The total consolidated purchases for all segments together increased from 2,051 million in 2020 to 3,499 million in 2024. This represents a significant increase in overall capital expenditures, indicating an expanding investment in property, equipment, and capitalized software over the five years.
In summary, the data reflects generally positive growth trends in capital expenditures across nearly all segments, particularly within the Optum business. Despite minor fluctuations or a slight dip in some segments in the final year, the overall pattern suggests increased investment over time, potentially supporting growth or modernization strategies within the organization.
Depreciation and amortization
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|
UnitedHealthcare | |||||
Optum Health | |||||
Optum Insight | |||||
Optum Rx | |||||
Optum | |||||
Consolidated |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- UnitedHealthcare Segment
-
The depreciation and amortization expenses for the UnitedHealthcare segment showed some fluctuations over the observed period. The amount increased from 920 million US dollars in 2020 to a peak of 1,004 million in 2021, followed by a decline to 973 million in 2022. The figure then slightly rebounded to 989 million in 2023 but decreased again to 889 million by 2024. Overall, this segment experienced a moderate decline in depreciation and amortization charges from 2021 onward.
- Optum Health Segment
-
Optum Health displayed a consistent upward trend throughout the period. Starting at 703 million US dollars in 2020, the depreciation and amortization expenses increased annually, reaching 818 million in 2021, 943 million in 2022, 1,058 million in 2023, and 1,123 million in 2024. This continuous growth indicates expanding capital asset utilization or increased amortizable intangible assets within this segment.
- Optum Insight Segment
-
Similar to Optum Health, the Optum Insight segment exhibited a steady rise in depreciation and amortization expenses. Beginning at 670 million US dollars in 2020, the expense saw modest growth to 684 million in 2021, then more significant increments to 841 million in 2022, 1,229 million in 2023, and 1,294 million in 2024. The sharper increase from 2022 onward suggests increased investments in capital assets or intangible resources in this part of the business.
- Optum Rx Segment
-
The Optum Rx segment's depreciation and amortization charges remained relatively stable initially, with a slight decrease from 598 million in 2020 to 597 million in 2021. Thereafter, there were consistent annual increases to 643 million in 2022, 696 million in 2023, and 793 million in 2024. This trend points to gradual growth and possibly increased asset bases contributing to this segment's depreciation and amortization expenses.
- Combined Optum Segment
-
The total depreciation and amortization for the Optum umbrella segment (comprising Health, Insight, and Rx) grew steadily through the entire timeframe. The value rose from 1,971 million US dollars in 2020 to 2,099 million in 2021, then accelerated to 2,427 million in 2022, 2,983 million in 2023, and 3,210 million in 2024. This pattern indicates sustained capital investment growth and expansion of amortizable assets across the Optum divisions collectively.
- Consolidated Totals
-
The overall depreciation and amortization expenses consolidated across all reportable segments increased from 2,891 million US dollars in 2020 to 3,103 million in 2021, followed by steady increments to 3,400 million in 2022, 3,972 million in 2023, and 4,099 million in 2024. The steady upward trajectory reflects ongoing capital expenditures and amortization activities at the company-wide level, primarily driven by the robust growth in the Optum segments, which more than compensated for the modest decline in the UnitedHealthcare segment.